Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Sherlock Biosciences Licenses US Dx Rights to CRISPR-Cas12 From Tolo Biotech

Sherlock Biosciences Licenses US Dx Rights to CRISPR-Cas12 From Tolo Biotech

Dec 04, 2020
|
staff reporter

NEW YORK – Sherlock Biosciences on Friday said that it has licensed exclusive US rights to CRISPR-Cas12 diagnostic technology from Shanghai-based Tolo Biotech.

In return, Sherlock has granted Tolo exclusive rights to the CRISPR-Cas13 SHERLOCK diagnostic platform in Greater China. Financial details of the agreement have not been disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

California Strain

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

Boosting Viral Surveillance

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

Nucleic Acids Research Studies on Pan-Cancer MiRNA Biogenesis Mutations, Skeletal Methylation, More

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

Lander Nominated for Science Advisor

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

Feb
11
Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
17
Featured Webinar

Single-Cell Multiomics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19

Sponsored by
BioLegend

Host immune responses play a central role in controlling SARS-CoV-2 infection, but they remain incompletely characterized and understood.

Feb
18
Featured Webinar

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

What's Popular?

In Molecular Diagnostics

  1. Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

  2. Lucira Health Files for $115M IPO

  3. CMS Finalizes Blood-Based Colon Cancer Screening NCD with Non-Coverage for Epi ProColon

  4. JP Morgan Healthcare Conference 2021, Day 3: Exact Sciences, Danaher, NanoString, Bio-Techne, More

  5. Pacific Biosciences CEO Discusses Q4 Results, New Sequencing Platforms at JP Morgan

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.